DXCM

DexCom, Inc.

Healthcare
73.45 -1.42 -1.90% Market Closed
2026-06-02 • USD

Key Metrics

Market Cap 28.34B
EV —
Shares Out 385.87M
Revenue (ttm) 4.82B
Net Income 930.40M
Beta —
P/E 30.40
Forward P/E —
EPS (ttm) $2.33
P/S 5.87
P/B 9.57
P/FCF —
P/C —
EV/Sales —
EV/EBITDA —
ROA 14.03%
ROE 33.65%
ROIC 26.22%
Gross Margin 61.5%
Oper. Margin 21.45%
Profit Margin 19.31%
Debt/Eq 0.03
LT Debt/Eq —
Quick Ratio —
Current Ratio 1.95
Book/sh 7.68
Cash/sh 2.9
Div Yield —
Div TTM —
Payout Ratio —
SMA20 10.95%
SMA50 14.42%
SMA200 8.38%
Volume 3,751,604
Avg Volume 5.20M
Rel Volume —
Perf Week -0.39%
Perf Month 23.49%
Perf Quarter 3.90%
Perf Half Y 12.15%
Perf YTD 10.67%
Perf Year -14.33%
Perf 3Y -41.08%
Perf 5Y -23.27%

Factor Lens

Seasonal Performance

Financial Trends

Revenue & Net Income

Earnings Per Share

Margins

Cash Flow

Company Overview

DexCom, Inc. is a medical device company primarily focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians around the world. The company received FDA approval and commercialized its first product in 2006. Key product offerings include the Dexcom G7 Continuous Glucose Monitoring System (approved December 2022), the Dexcom G7 15 Day system (approved April 2025), the Dexcom G6, Dexcom ONE+ (CE Mark approved November 2023), and Stelo (launched August 2024), an over-the-counter glucose biosensor for adults with prediabetes and Type 2 diabetes who do not use insulin. The company also offers Dexcom Share and Dexcom Follow remote monitoring systems and has entered into multiple collaboration agreements with insulin delivery system providers. The company serves patients with Type 1 and Type 2 diabetes globally, with products cleared for use in the United States, European Union, and other markets. As of December 31, 2025, the company had approximately 3.5 million active customers globally.

Name
DexCom, Inc.
Industry
Medical Devices
CEO
Jacob Leach · President and Chief Executive Officer
Employees
—
IPO Date
2018-08-15
Phone
(858) 200-0200
Address
6340 Sequence Drive, San Diego, CA 92121
Website
www.dexcom.com

Key Executives

Name Title FY Pay
Kevin Sayer Executive Chairman of the Board —
Jacob Leach President and Chief Executive Officer —

Latest News